Effect of Empagliflozin on Ventricular Repolarization.

• Status: Recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The present project aims to investigate if the empagliflozin has an antiarrhythmic action. Analyzing the T-wave heterogeneity index, a new electrocardiographic risk marker associated with the prediction of cardiovascular risk, in diabetic patients and coronary artery disease, the investigators will verify if empagliflozin is associated with a reduction in electrical instability.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Treatments: Empagliflozin

Criteria

Inclusion Criteria:

• • Age ≥ 18 years;

• Fasting glycemia> 100 mg/dl or previous diagnosis of type 2 diabetes mellitus;

• Coronary artery disease, defined by one of the following criteria: the antecedent of myocardial infarction; the evidence of significant coronary stenosis in previous coronary angiography; the noninvasive positive test for ischemia (stress electrocardiogram, stress echocardiogram, stress scintigraphy)

• TWH ≥ 80 microvolts

Exclusion Criteria:

• Chronic renal insufficiency with glomerular filtration rate ≤ 45 ml / min / 1.73m2;

• Hepatic insufficiency (determined by Child-Pugh, B or C classification);

• Age ≥ 85 years;

• 12-lead resting electrocardiogram with the following changes: intraventricular conduction disorders (bundle branch block), pacemaker rhythm, atrial fibrillation or flutter, artifact stroke distortion or baseline fluctuation